Production of vaccines against leading biowarfare toxins can utilize DNA scientific technology

Advanced Drug Delivery Reviews

Volumn 57, Issue 9, 2005, Pages 1415-1423

  Middlebrook, John L ^a  

^a NONE

Author keywords

Aerosol challenge; Antibody protection; Botulinum toxin; Immunization; Protein synthesis inhibition; Ricin

Indexed keywords

DNA; GENES; TOXIC MATERIALS;

BIOLOGICAL WARFARE AGENTS; NATURAL TOXINS;

VACCINES;

BACTERIAL VACCINE; BOTULINUM TOXIN; BOTULINUM TOXIN VACCINE; DNA VACCINE; EPITOPE; RICIN VACCINE; UNCLASSIFIED DRUG; VACCINE; VIRUS VECTOR;

BACTERIAL GENE; BIOLOGICAL WARFARE; BOTULISM; HIGH RISK POPULATION; HOST RESISTANCE; HUMAN; INFECTION PREVENTION; INFECTION RESISTANCE; MOLECULAR CLONING; MUCOSAL IMMUNITY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REPLICON; REVIEW; SEROTYPE; VACCINE PRODUCTION; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS ASSEMBLY; VIRUS GENE;

ANIMALS; BIOLOGICAL WARFARE; BOTULINUM TOXINS; HUMANS; LETHAL DOSE 50; RICIN; TECHNOLOGY, PHARMACEUTICAL; TOXINS, BIOLOGICAL; VACCINES; VACCINES, DNA;

EID: 20344374719     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2005.01.016     Document Type: Review

References (51)

1. T.V. Inglesby, T. O'Toole, D.A. Henderson, J.G. Bertlett, M.S. Ascher, E. Eitzen, A.M. Friedlander, J. Jerberding, J. Gerberding, J. Hauer, J. Hughes, J. MsDade, M.T. Osterholm, G. Parker, T.M. Perl, P.K. Russell, and K. Tonat Anthrax as a Biological Weapon, 2002 updated recommendations for management JAMA 287 2002 2236 2252
2. M. Enserink Did bioweapons test cause a deadly smallpox outbreak? Science 296 2002 2116 2117
3. J.L. Middlebrook Protection strategies against botulinum toxin Adv. Exp. Med. Biol. 383 1995 93 98
4. D.M. Gill Bacterial toxins: a table of lethal amounts Microbiol. Rev. 46 1982 86 94
5. M.Z. Atassi, and M. Oshima Structure, activity, and immure (T and B Cell) recognition of botulinum neurotoxins Crit. Rev. 19 1999 219 260
6. K. Turton, J.A. Chaddock, and K.R. Acharya Botulinum and tetanus neurotoxins: structure, function and therapeutic utility Trends Biochem. Sci. 27 2002 552 558
7. C.L. Schenrund, B.R. DasGupta, C.A. Hughes, and N.J. Ringler Ganglioside-induced adherence of outline and tetanus neurotoxins to adducing J. Neurochem. 66 1966 2556 2561
8. F.J. Lebedda, and B.R. Singh Membrane channel activity and translocation of outline toxin and tetanus neurotoxins J. Toxicol., Toxin Rev. 1999 45 76
9. L.L. Simpson Identification of the characteristics that underlie outline toxin potency: implications for designing novel drugs Biochimie 82 2000 943 953
10. M.P. Byrne, and L.A. Smith Development of vaccines for prevention of botulism Biochemie 82 2000 955 966
11. C.L. Hatheway Toxoid of Clostridium outline: purification and immunization studies Appl. Environ. Microbiol. 31 1976 234 242
12. V.A. Montgomery, R.S. Makuch, J.E. Brown, and D.C. Hack The immunogenicity in humans of a botulinum type F vaccine Vaccine 18 2000 728 735
13. M.Z. Atassi, B.Z. Dolimbek, M. Hayakari, J.L. Middlebrook, B. Whitney, and M. Oshima Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species J. Protein. Chem. 15 1996 691 700
14. M.T. Dertzbaugh, and M.W. West Mapping of protective and cross reactive domains of type A neurotoxin of Clostridium botulinum Vaccine 14 1996 1538 1544
15. S. Bavari, D.D. Pless, E.R. Torres, F.J. Lebeda, and M.A. Olson Identifying the principal protective antigenic determinants of type A botulinum neurotoxin Vaccine 18 1998 1850 1856
16. H.F. LaPenotiere, M.A. Clayton, and J.L. Middlebrook Expression of a large nontoxic fragment of botulinum neurotoxin serotype A and its use as a immunogen Toxicon 33 1995 1383 1386
17. N.F. Fairweather, V.A. Lyness, and D.J. Maskell Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli Infect. Immun. 55 1987 2541 2545
18. A.J. Makoff, S.P. Ballantine, A.E. Smallwood, and N.F. Fairweather Expression of tetanus toxin fragment C in E. coli: its purification and potential use as a vaccine Bio/Technology 7 1989 1043 1046
19. M.A. Clayton, J.M. Clayton, D.R. Brown, and J.L. Middlebrook Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli Infect. Immun. 63 1995 2728 2742
20. L.A. Smith Development of recombinant vaccines for botulinum toxin Toxicon 36 1998 1539 1548
21. M.P. Byrne, T.J. Smith, V.A. Montgomery, and L.A. Smith Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate Infect. Immun. 66 1998 4817 4822
22. M.F. Byrne, R.W. Titball, J. Holley, and L.A. Smith Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris Protein Expr. Purif. 18 2000 327 337
23. K.J. Potter, M.A. Bevins, E.V. Vassilieva, V.R. Chiruvolu, T. Smith, L.A. Smith, and M.M. Meagher Production and purification of the heavy chain fragment C of botulinum neurotoxin, serotype B, expressed in the methyltrophic yeast Pichia pastoris Protein Expr. Purif. 13 1998 357 365
24. K.J. Potter, W. Zhang, L.A. Smith, and M.M. Meagher Production and purification of the heavy chain of the heavy chain of botulinum neurotoxin, serotype A, expressed in the methyltrophic yeast Pichia pastoris Protein Expr. Purif. 19 2000 393 402
25. W. Zhang, M.A. Bevins, B.A. Plantz, L.A. Smith, and M.W. Meagher Modeling Pichia pastoris growth on methanol and optimizing the production of a recombinant protein, the heavy-chain fragment of botulinum neurotoxin, serotype A Biotechnol. Bioeng. 70 2000 1 8
26. J.L. Holly, M. Elmore, M. Mauchline, N. Minton, and R. Titball Cloning, expression and evaluation of a recombinant sub-unit vaccine against Clostridium botulinum type F toxin Toxin 19 2001 288 297
27. L.A. Woodward, H. Arimitsu, R. Hirst, and K. Oguma Expression of HC subunits from Clostridium botulinum types C and D and their evaluation as candidate vaccine antigens in mice Infect. Immun. 71 2003 2941 2944
28. R.H. Shyu, M.F. Shaio, S.S. Tang, H.F. Shyu, C.F. Lee, M.H. Tsai, J.E. Smith, H.H. Hsang, J.J. Wey, J.L. Huang, and H.H. Chang DNA vaccination using the fragment C of botulinum neurotocin type A provided protective immunity in mice J. Biomed. Sci. 7 2000 51 57
29. J. Clayton, and J.L. Middlebrook Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotoxin serotype A Vaccine 18 2000 1855 1862
30. N.L. Davis, I.J. Caley, K.W. Brown, M.R. Betts, D.M. Irlbeck, K.M. McGrath, M.J. Connell, D.C. Montefiori, J.A. Frelinger, K. Swanstrom, P.R. Johnson, and R.E. Johnston Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles J. Virol. 74 2000 371 378
31. P.M. Pushko M. Parker J. Geisbert D. Negley A. Schmaljohn P. Jahrling J. Smith Venezuelan equine encephalitis replicon vector: immunogenicity studies with Ebola NP and GP genes in guinea pigs 1997 Cold Spring Harbor Laboratory Press Cold Spring Harbor, NY
32. J.S. Lee, P. Pushko, M.D. Parker, M.T. Dertzbaugh, L.A. Smith, and J.S. Smith Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan Equine Encephalitis virus vector system Infect. Immun. 69 2001 5709 5715
33. S. Foynes, J.L. Holley, H.S. Garmory, R.W. Titball, and N.W. Fairweather Vaccination against type A botulinum toxin using attenuated Salmonella enterica var Typhimurium strains expressing the BoNT/FHC fragment Vaccine 21 2003 1052 1059
34. N. Kiyatkin, A.B. Maksymowych, and L.L. Simpson Induction of an immune response by an oral administration of recombinant botulinum toxin Infect. Immun. 65 1997 4586 4591
35. N. Mahmut, K. Inoue, Y. Fujinaga, H. Arimitsu, Y. Sakaguchi, L. Hughes, R. Hirst, T. Murphy, T. Tsuji, T. Watanabe, T. Ohayama, T. Karasawa, S. Nakamura, K. Yokata, and K. Oguma Mucosal immunisation with Clostridium botulinum type C 16 S toxoid and its non-toxoic component J. Med. Microbiol. 51 2002 813 820
36. J.M. Lord, L.M. Roberts, and J.D. Robertus Ricin: structure, mode of action, and some current applications FASEB J. 8 1994 201 208
37. W. Montfort, J.E. Villafranca, A.F. Monzingo, S. Ernst, B. Katzin, E. Rutenber, N.H. Xuong, R. Hamlin, and J.D. Robertus The three dimensional structure of ricin at 2.8A J. Biol. Chem. 262 1987 5398 5403
38. E. Rutenber, B.J. Katzin, E.J. Collins, D. Mlsna, S. Eenst, M.P. Ready, and J.D. Robertus The crystallographic refinement of ricin at 2.5A Res. Prot. 10 1991 240 250
39. B.J. Katzin, E.J. Collins, and J.D. Robertus The structure of ricin A chain at 2.5A Proteins 10 1991 251 259
40. E. Ruterner, and J.D. Robertus The structure of ricin B chain at 2.5A resolution Proteins 10 1991 260 269
41. D.L. Newton, R. Wales, P.T. Richardson, S. Walbridge, S.K. Saxena, E.J. Akerman, L.M. Roberts, J.M. Lord, and R.J. Youle Cell surface and intracellular functions for ricin galactose binding J. Biol. Chem. 267 1992 11917 11922
42. G.D. Griffiths, G.D. Lindsay, A.C. Allenby, S.C. Bailey, J.W. Scawin, P. Rice, and D.G. Upshall Protection against inhalation toxicity of ricin and abrin by immunization Hum. Exp. Toxicol. 14 1995 155 164
43. Y. Changhong, W.L. Rill, R. Malli, J. Hewetson, R. Tammeriello, and M. Kende Dependence of ricin toxoid vaccine on the structure of poly(lactide-co-glycolide) microparticle carriers Vaccine 13 1995 645 651
44. Y. Changhong, W.L. Rill, R. Malli, J. Hewetson, H. Naseem, R. Tammariello, and M. Kende Intranasal stimulation of long-lasting immunity against aerosol ricin challenge with ricin toxoid vaccine encapulated in polymeric microspheres Vaccine 14 1996 1031 1038
45. Yan, W.L. Rill, R. Malli, J. Hewetson, H. Naseem, R. Tammariello, and M. Kende Intranasal stimulation of long-lasting immunity against aerosol ricin challenge with ricin toxoid vaccine encapsulated in polymeric microspheres Vaccine 14 1996 1031 1036
46. M. Kende, C. Tan, J. Hewetson, M.A. Frick, W.L. Rill, and R. Tammariello Oral immunization of mice with ricin toxoid encapsulated in polymeric microspheres against aerosol challenge Vaccine 20 2002 1681 1691
47. G.D. Griffiths, S.C. Bailey, J.L. Hambrook, M. Keyte, P. Jayasekera, J. Miles, and E. Williamson Liposomally-encapsulated ricin toxoid vaccine delivered intratracheally elicits a good immune response and protects against a lethal pulmonary dose of ricin toxin Vaccine 15 1997 1933 1939
48. G.D. Griffiths, S.C. Bailey, J.L. Hambrook, and M.P. Keyte Local and systemic responses against ricin toxin promoted by toxoid or peptide vaccines alone or in liposomal formulations Vaccine 16 1998 530 535
49. G.D. Griffiths, G.J. Phillips, and S.C. Bailey Comparison of the quality of protection cited by toxoid and peptide liposomal vaccine formulations against ricin as assessed by markers of inflammation Vaccination 17 1999 2562 2568
50. J.E. Smallshaw, A. Firan, J.R. Fulmer, S.L. Ruback, V. Ghetie, and E.S. Vitetta A novel recombinant vaccine which protects mice against ricin intoxication Vaccine 20 2002 3422 3437
51. R. Baluna, J. Rizo, B.E. Gordon, V. Ghetie, and E.S. Vitetta Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome Proc. Natl. Acad. Sci. U. S. A. 96 1999 3957 3962